Sanofi, Walvax COVID-19 Vaccine Phase 3 Trials to Commence in Mexico: Reuters

Trending Investment Opportunities

Mexico Foreign Minister Marcel Ebrard said that the country would begin phase 3 trials for COVID-19 vaccines by Sanofi SA SNY and China's Walvax soon.
Mexico's health regulator Cofepris approved trials of the Sanofi vaccine, which uses a recombinant protein-based technology, Ebrard added, reports Reuters.
"In Mexico, phase 3 of very diverse vaccines have already been carried out or are being carried out," Ebrard said in a virtual event. "Two new phase 3 (trials) are about to start... one is Walvax, which is a Chinese vaccine.. and today they notified us via Cofepris, (the other is) Sanofi, with a recombinant protein."
Mexico's own "Patria" COVID-19 vaccine will enter phase two trials shortly, Ebrard said. Emergency use approval for the home-grown vaccine is expected in 2021.
Mexico has so far received about 33.5 million vaccine doses from foreign suppliers, including Pfizer Inc PFE, AstraZeneca Plc AZN, and China's Sinovac Biotech Ltd SVA, according to government data.
Ebrard said Mexico would have 40 million doses by June, increasing to 65 million by July.
Price Action: SNY shares are up 0.71% at $54.05 during the premarket session on the last check Tuesday.